These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 26181273)

  • 21. Innovative Clinical Trial Designs Lead to New Drug Approvals.
    Miller DJ
    ONS Connect; 2016 Mar; 31(3):22. PubMed ID: 27044204
    [No Abstract]   [Full Text] [Related]  

  • 22. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The changing world of oncology drug development-A global pharmaceutical company's perspective.
    Galbraith S
    Chin Clin Oncol; 2014 Jun; 3(2):20. PubMed ID: 25841416
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of multiple endpoints and approval paths depicts a decade of FDA oncology drug approvals.
    Shea MB; Roberts SA; Walrath JC; Allen JD; Sigal EV
    Clin Cancer Res; 2013 Jul; 19(14):3722-31. PubMed ID: 23665737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Change coming to FDA. Law should speed approvals, but critics say it's not enough.
    Hensley S
    Mod Healthc; 1997 Nov; 27(46):28. PubMed ID: 10174355
    [No Abstract]   [Full Text] [Related]  

  • 26. Recent drug approvals from the US FDA and EMEA: what the future holds.
    Pevarello P
    Future Med Chem; 2009 Apr; 1(1):35-48. PubMed ID: 21426069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Error in Text and Table. Influence of Institutional Culture and Policies on Do-Not-Resuscitate Decision Making at the End of Life.
    Dzeng
    JAMA Intern Med; 2015 Jul; 175(7):1247. PubMed ID: 26146923
    [No Abstract]   [Full Text] [Related]  

  • 28. Economic burden of illness imposed by severe sepsis in Austria.
    Schmid A; Schneider H; Adlof A; Smolle KH; Edelmann G; Sporn P; Frass M; Sumann G; Koller W; Schobersberger W
    Wien Klin Wochenschr; 2002 Aug; 114(15-16):697-701. PubMed ID: 12602114
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapies for inborn errors of metabolism: what has the orphan drug act delivered?
    Talele SS; Xu K; Pariser AR; Braun MM; Farag-El-Massah S; Phillips MI; Thompson BH; Coté TR
    Pediatrics; 2010 Jul; 126(1):101-6. PubMed ID: 20566615
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Error in Text and Table. Primary Care Provider-Delivered Smoking Cessation Interventions and Smoking Cessation Among Participants in the National Lung Screening Trial.
    JAMA Intern Med; 2015 Sep; 175(9):1587-8. PubMed ID: 26348525
    [No Abstract]   [Full Text] [Related]  

  • 31. The impact of pharmaceutical innovation on premature mortality, cancer mortality, and hospitalization in Slovenia, 1997-2010.
    Lichtenberg FR
    Appl Health Econ Health Policy; 2015 Apr; 13(2):207-22. PubMed ID: 25564200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of Medicare Part D on out-of-pocket drug costs and medical use for patients with cancer.
    Kircher SM; Johansen ME; Nimeiri HS; Richardson CR; Davis MM
    Cancer; 2014 Nov; 120(21):3378-84. PubMed ID: 24962682
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II.
    Garrison LP; Mansley EC; Abbott TA; Bresnahan BW; Hay JW; Smeeding J
    Value Health; 2010; 13(1):8-13. PubMed ID: 19883405
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Data Error in Table 2 and Typographic Errors in Text in: Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers and Cardiovascular Outcomes in Chronic Dialysis Patients: A Population-Based Cohort Study.
    Arch Intern Med; 2012 Jun; 172(12):908. PubMed ID: 23752789
    [No Abstract]   [Full Text] [Related]  

  • 35. The price of innovation: new estimates of drug development costs.
    DiMasi JA; Hansen RW; Grabowski HG
    J Health Econ; 2003 Mar; 22(2):151-85. PubMed ID: 12606142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A medication error prevention survey: five years of results.
    Cusano FL; Chambers CR; Summach DL
    J Oncol Pharm Pract; 2009 Jun; 15(2):87-93. PubMed ID: 19036904
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence of comparative efficacy should have a formal role in European drug approvals.
    Sorenson C; Naci H; Cylus J; Mossialos E
    BMJ; 2011 Sep; 343():d4849. PubMed ID: 21896610
    [No Abstract]   [Full Text] [Related]  

  • 38. The effect of new drug approvals on HIV mortality in the US, 1987-1998.
    Lichtenberg FR
    Econ Hum Biol; 2003 Jun; 1(2):259-66. PubMed ID: 15463977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Error in Text and Table.
    JAMA Intern Med; 2016 Apr; 176(4):568. PubMed ID: 26974880
    [No Abstract]   [Full Text] [Related]  

  • 40. Cancer biomarkers--an invitation to the table.
    Dalton WS; Friend SH
    Science; 2006 May; 312(5777):1165-8. PubMed ID: 16728629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.